Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to...
7 insider purchases on record · latest filing 2019-11-20.
Insiders have also filed 270 sale transactions at REPL.